FBRX insider trading
NasdaqCM HealthcareForte Biosciences, Inc.: insider trade history from SEC Form 4 filings.
About Forte Biosciences, Inc.
Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's lead product candidate is the FB-102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for various autoimmune and autoimmune-related indications, such as graft-vs-host disease, vitiligo, and alopecia areata, as well as for celiac disease and non-segmental vitiligo. Forte Biosciences, Inc. is headquartered in Dallas, Texas.
Company website: www.fortebiorx.com
FBRX insider activity at a glance
FilingIQ tracks 96 insider transactions for FBRX in filings since Jun 29, 2020. The most recent transaction is dated Aug 27, 2026.
Across the full history, 18 open-market purchases
and 3 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on FBRX insider trades is 65.3/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest FBRX Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Top insiders trading FBRX
Frequently asked
- How many insider trades does FilingIQ track for FBRX?
- FilingIQ tracks 96 Form 4 insider transactions for FBRX (Forte Biosciences, Inc.), covering filings from Jun 29, 2020 onwards. 4 of those are dated within the last 90 days.
- Are FBRX insiders net buyers or net sellers?
- Across the full Form 4 history for FBRX, 18 transactions (19%) were open-market purchases and 3 (3%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does FBRX insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
- What sector is FBRX in?
- Forte Biosciences, Inc. (FBRX) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $338.35M.
Methodology & sources
Every FBRX insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.